Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale

The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients... Cardiol Ther (2018) 7:101–106 https://doi.org/10.1007/s40119-018-0112-3 STUDY PROTOCOL The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale . . . Alhasan Mujtaba Mohammed A. Taher Mazin A. Hazza . . . Hassan M. Al-Rubaye Asaad H. Kata Hamid AbdulWahab AbdulAmeer AbdulBari Hayder K. AlRubay Received: April 11, 2018 / Published online: May 21, 2018 The Author(s) 2018 center will be allocated in a 1:1 ratio to receive ABSTRACT either spironolactone 200 mg single dose or placebo in addition to their usual Introduction: Patients undergoing coronary premedication. catheterization are at high risk of developing Planned Outcomes: Primary end point will be contrast-induced nephropathy (CIN) acute kid- CIN defined as more than 25% or 0.3 mg/dl ney injury (AKI). Several approaches have been elevation in serum creatinine (S.Cr.) from supposed to limit such an effect but with mixed baseline during the first 2–3 days after the pro- results or non-practical methods. Spironolac- cedure. We hope to identify or answer an tone is supposed to be effective as a nephro- important question regarding CIN in such high- protective agent in animal studies. This study risk patients. will try to measure the effect of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale

Download PDF
6 pages

Loading next page...
 
/lp/springer_journal/the-effect-of-spironolactone-on-the-incidence-of-contrast-induced-fVNGoUgl3d
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-018-0112-3
Publisher site
See Article on Publisher Site

Abstract

Cardiol Ther (2018) 7:101–106 https://doi.org/10.1007/s40119-018-0112-3 STUDY PROTOCOL The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale . . . Alhasan Mujtaba Mohammed A. Taher Mazin A. Hazza . . . Hassan M. Al-Rubaye Asaad H. Kata Hamid AbdulWahab AbdulAmeer AbdulBari Hayder K. AlRubay Received: April 11, 2018 / Published online: May 21, 2018 The Author(s) 2018 center will be allocated in a 1:1 ratio to receive ABSTRACT either spironolactone 200 mg single dose or placebo in addition to their usual Introduction: Patients undergoing coronary premedication. catheterization are at high risk of developing Planned Outcomes: Primary end point will be contrast-induced nephropathy (CIN) acute kid- CIN defined as more than 25% or 0.3 mg/dl ney injury (AKI). Several approaches have been elevation in serum creatinine (S.Cr.) from supposed to limit such an effect but with mixed baseline during the first 2–3 days after the pro- results or non-practical methods. Spironolac- cedure. We hope to identify or answer an tone is supposed to be effective as a nephro- important question regarding CIN in such high- protective agent in animal studies. This study risk patients. will try to measure the effect of

Journal

Cardiology and Therapy – Springer Journals

Published: May 21, 2018

References

  • Contrast-induced acute kidney injury following PCI
    Tehrani, S
  • Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention
    Tziakas, D
  • Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction
    Sadeghi, HM; Stone, GW; Grines, CL
  • Aggressive hydraTion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention to prevent contrast-induced nephropathy (ATTEMPT): study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy following carDiac catheterization) trial
    Liu, M
  • Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty
    Droppa, M; Desch, S; Blase, P
  • Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial
    Thayssen, P; Lassen, JF; Jensen, SE
  • The effect of spironolactone on acute kidney injury after cardiac surgery: a randomized, placebo-controlled trial
    Navarro, RB
  • Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone
    Mejia-Vilet, JM
  • Recovery from ischemic acute kidney injury by spironolactone administration
    Sanchez-Pozos, K
  • Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery
    Pretorius, M
  • Cystatin C and contrast-induced acute kidney injury
    Briguori, C
  • Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury
    Kellum, JA; Lameire, N; Aspelin, P; Barsoum, RS; Burdmann, EA; Goldstein, SL; Herzog, CA; Joannidis, M; Kribben, A; Levey, AS; MacLeod, AM; Mehta, RL; Murray, PT; Naicker, S; Opal, SM; Schaefer, F; Schetz, M; Uchino, S
  • Neutrophil gelatinase-associated lipocalin in the prediction of contrast-induced nephropathy: a systematic review and meta-analysis
    Tong, J
  • Hyperkalemia in heart failure
    Sarwar, CM; Papadimitriou, L; Pitt, B
  • Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial
    Butler, J; Anstrom, KJ; Feller, M
  • The role of serum cystatin C in the early detection of contrast-induced nephropathy after coronary intervention
    Al-Tu’ma, FJ
  • Contrast-induced nephropathy in diabetic and non-diabetic patients after coronary intervention
    Nassir, FS
  • Predicting contrast-induced nephropathy post coronary intervention: a prospective cohort study
    Taher
  • Risk prediction models for contrast-induced nephropathy: systematic review
    Silver, SA
  • How strong is the evidence for sodium bicarbonate to prevent contrast-induced acute kidney injury after coronary angiography and percutaneous coronary intervention?
    Dong, Y
  • Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial
    Brar, SS
  • Rationale and design of the aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure (ATHENA-HF) trial
    Butler, J
  • Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure
    Ferreira, JP; Santos, M; Almeida, S; Marques, I; Bettencourt, P; Carvalho, H
  • Spironolactone dose–response relationships in healthy subjects
    McInnes, CT